VENLO (dpa-AFX) - MDxHealth SA (MXDHF.PK) announced Wednesday that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR or MSP technology to Qiagen N.V. (QGEN) for use in its new CE-marked QIAsure assay to determine cervical cancer risk.
MDxHealth will receive a signing fee plus royalties from future test sales utilizing this technology.
Under the terms of the agreement, Qiagen has licensed the use of MDxHealth's MSP technology, a proprietary DNA-methylation specific PCR methodology, for the development and commercialization of its new diagnostic test which differentiates patients' risk of developing cervical cancer.
QIAGEN reported that the QIAsure test is a highly complementary addition to its leading human papilloma virus or HPV franchise. Women screening positive for HPV, or with abnormal cells identified by cytology, are at increased risk of developing cervical cancer. The QIAsure test is the next logical step to assess this risk.
Jan Groen, CEO of MdxHealth, said, 'We are pleased that our Methylation technology can further support QIAGEN's efforts to improve women's health. Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528,000 new cases diagnosed and 266,000 deaths each year, so clearly this is an important test.'
Copyright RTT News/dpa-AFX